Amoéba S.A. (EPA:ALMIB)

France flag France · Delayed Price · Currency is EUR
0.850
0.00 (0.00%)
Apr 28, 2026, 5:35 PM CET
-22.30%
Market Cap 58.55M
Revenue (ttm) 695.45K
Net Income (ttm) -8.30M
Shares Out 68.89M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 197,862
Average Volume 262,973
Open 0.850
Previous Close 0.850
Day's Range 0.841 - 0.852
52-Week Range 0.780 - 1.444
Beta 0.20
RSI 44.02
Earnings Date Apr 17, 2026

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France. [Read more]

Sector Materials
Founded 2010
Employees 23
Stock Exchange Euronext Paris
Ticker Symbol ALMIB
Full Company Profile

Financial Performance

In 2025, Amoéba's revenue was 695,449, an increase of 15.60% compared to the previous year's 601,600. Losses were -8.30 million, 26.0% more than in 2024.

Financial Statements

News

There is no news available yet.